Allogene Therapeutics, Inc. Operating Cash Flow
Allogene Therapeutics, Inc. (ALLO) reported Operating Cash Flow of -$44.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Allogene Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$32.00M.
- Allogene Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.91M.
- Allogene Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$27.60M.
- Allogene Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$29.69M.
- Allogene Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$149.25M.
- Allogene Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$200.30M.
- Allogene Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$237.73M.
- Allogene Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$220.52M.
| Period end | Net Cash Provided by (Used in) Operating Activities 1 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$32.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$44.91M 10-Q · filed 2026-08-12 | -$72.51M derived: sum of 3 quarters · filed 2026-08-12 | -$102.20M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$12.91M 10-Q · filed 2026-05-13 | -$40.51M derived: sum of 2 quarters · filed 2026-05-13 | -$70.20M derived: sum of 3 quarters · filed 2026-05-13 | -$109.23M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$27.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$57.29M derived: sum of 2 quarters · filed 2026-03-12 | -$96.32M derived: sum of 3 quarters · filed 2026-08-12 | -$149.25M 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$29.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$68.72M derived: sum of 2 quarters · filed 2026-08-12 | -$121.65M 10-Q · filed 2025-11-06 | -$158.34M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$39.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$91.96M 10-Q · filed 2026-08-12 | -$128.66M derived: sum of 3 quarters · filed 2026-08-12 | -$172.77M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$52.93M 10-Q · filed 2026-05-13 | -$89.63M derived: sum of 2 quarters · filed 2026-05-13 | -$133.74M derived: sum of 3 quarters · filed 2026-05-13 | -$197.33M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$36.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$80.81M derived: sum of 2 quarters · filed 2026-03-12 | -$144.40M derived: sum of 3 quarters · filed 2026-03-12 | -$200.30M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$44.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$107.70M derived: sum of 2 quarters · filed 2025-11-06 | -$163.60M 10-Q · filed 2025-11-06 | -$217.31M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$63.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$119.49M 10-Q · filed 2025-08-13 | -$173.19M derived: sum of 3 quarters · filed 2025-08-13 | -$228.72M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$55.90M 10-Q · filed 2025-05-13 | -$109.61M derived: sum of 2 quarters · filed 2025-05-13 | -$165.14M derived: sum of 3 quarters · filed 2025-05-13 | -$226.99M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$53.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$109.24M derived: sum of 2 quarters · filed 2025-03-13 | -$171.09M derived: sum of 3 quarters · filed 2025-03-13 | -$237.73M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$55.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$117.39M derived: sum of 2 quarters · filed 2024-11-07 | -$184.03M 10-Q · filed 2024-11-07 | -$246.12M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$61.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$128.50M 10-Q · filed 2024-08-07 | -$190.59M derived: sum of 3 quarters · filed 2024-08-07 | -$238.25M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | -$66.64M 10-Q · filed 2024-05-13 | -$128.74M derived: sum of 2 quarters · filed 2024-05-13 | -$176.39M derived: sum of 3 quarters · filed 2024-05-13 | -$218.92M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$62.10M derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | -$109.75M derived: sum of 2 quarters · filed 2024-03-14 | -$152.28M derived: sum of 3 quarters · filed 2024-03-14 | -$220.52M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | -$47.66M derived: 10-K 9 month − 10-K 6 month · filed 2024-03-14 | -$90.19M derived: sum of 2 quarters · filed 2024-03-14 | -$158.42M 10-K · filed 2024-03-14 | -$203.86M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | -$42.53M derived: 10-K 6 month − 10-K 3 month · filed 2024-03-14 | -$110.77M 10-K · filed 2024-03-14 | -$156.20M derived: sum of 3 quarters · filed 2024-03-14 | -$205.08M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | -$68.24M 10-K · filed 2024-03-14 | -$113.67M derived: sum of 2 quarters · filed 2024-03-14 | -$162.55M derived: sum of 3 quarters · filed 2024-03-14 | -$203.72M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | -$45.44M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$94.31M derived: sum of 2 quarters · filed 2024-03-14 | -$135.48M derived: sum of 3 quarters · filed 2024-03-14 | -$184.81M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | -$48.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$90.05M derived: sum of 2 quarters · filed 2022-11-02 | -$139.38M 10-Q · filed 2022-11-02 | -$149.35M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | -$41.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$90.50M 10-Q · filed 2022-08-09 | -$100.47M derived: sum of 3 quarters · filed 2024-03-14 | -$138.06M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | -$49.33M 10-Q · filed 2022-05-04 | -$59.30M derived: sum of 2 quarters · filed 2024-03-14 | -$96.89M derived: sum of 3 quarters · filed 2024-03-14 | -$123.61M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | -$9.97M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$47.56M derived: sum of 2 quarters · filed 2024-03-14 | -$74.28M derived: sum of 3 quarters · filed 2024-03-14 | -$115.09M 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | -$37.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$64.31M derived: sum of 2 quarters · filed 2021-11-04 | -$105.12M 10-Q · filed 2021-11-04 | -$155.38M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | -$26.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$67.53M 10-Q · filed 2021-08-04 | -$117.80M derived: sum of 3 quarters · filed 2022-02-23 | -$149.73M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | -$40.81M 10-Q · filed 2021-05-05 | -$91.08M derived: sum of 2 quarters · filed 2022-02-23 | -$123.01M derived: sum of 3 quarters · filed 2022-02-23 | -$147.90M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | -$50.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$82.20M derived: sum of 2 quarters · filed 2022-02-23 | -$107.09M derived: sum of 3 quarters · filed 2022-02-23 | -$137.35M 10-K · filed 2022-02-23 | |
| 2019-09-30 | -$31.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$56.83M derived: sum of 2 quarters · filed 2020-11-04 | -$87.08M 10-Q · filed 2020-11-04 | -$108.56M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | -$24.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$55.15M 10-Q · filed 2020-08-05 | -$76.63M derived: sum of 3 quarters · filed 2021-02-25 | -$93.76M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$30.26M 10-Q · filed 2020-05-06 | -$51.74M derived: sum of 2 quarters · filed 2021-02-25 | -$68.87M derived: sum of 3 quarters · filed 2021-02-25 | -$74.91M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | -$21.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$38.61M derived: sum of 2 quarters · filed 2021-02-25 | -$44.66M derived: sum of 3 quarters · filed 2021-02-25 | -$44.65M 10-K · filed 2021-02-25 | |
| 2018-09-30 | -$17.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$23.18M derived: sum of 2 quarters · filed 2019-11-05 | -$23.17M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | -$6.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$6.04M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $5.00K 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |